Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its participation in an upcoming virtual fireside chat. CEO Marcio Souza will engage in a discussion with Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00am EST. The company specializes in developing treatments targeting neuronal excitation-inhibition imbalance in CNS disorders.
Praxis Precision Medicines (NASDAQ:PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a un prossimo incontro virtuale informale. Il CEO Marcio Souza parteciper脿 a una discussione con Yasmin Rahini, analista senior di ricerca presso Piper Sandler il 7 agosto 2025 alle 11:00 EST. L'azienda 猫 specializzata nello sviluppo di trattamenti che mirano a riequilibrare l'eccitazione e l'inibizione neuronale nei disturbi del SNC.
Praxis Precision Medicines (NASDAQ:PRAX), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su participaci贸n en una pr贸xima charla virtual informal. El CEO Marcio Souza sostendr谩 una conversaci贸n con Yasmin Rahini, analista senior de investigaci贸n de Piper Sandler el 7 de agosto de 2025 a las 11:00 am EST. La compa帽铆a se especializa en desarrollar tratamientos que abordan el desequilibrio entre excitaci贸n e inhibici贸n neuronal en trastornos del SNC.
Praxis Precision Medicines (NASDAQ:PRAX)电� 欷戩稊鞁犼步瓿� 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃樀鐢 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雼り皜鞓さ鐢 臧�靸� 雽�頇� 頄夓偓鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO Marcio Souza电� Piper Sandler鞚� 靹犾瀯 鞐瓣惮 攵勳劃臧� Yasmin Rahini鞕赌 2025雲� 8鞗� 7鞚� 鞓れ爠 11鞁�(霃欕秬 響滌鞁�)鞐� 雽�頇旊ゼ 雮橂垖 鞓堨爼鞛呺媹雼�. 鞚� 須岇偓电� 欷戩稊鞁犼步瓿� 歆堩櫂鞐愳劀 鞁犼步 頋ル秳瓿� 鞏奠牅 攵堦窢順曥潉 響滌爜鞙茧 頃樀鐢 旃橂鞝� 臧滊皽鞚� 鞝勲鞙茧 頃╇媹雼�.
Praxis Precision Medicines (NASDAQ:PRAX), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies pour les troubles du syst猫me nerveux central, a annonc茅 sa participation 脿 une prochaine discussion virtuelle informelle. Le PDG Marcio Souza participera 脿 un 茅change avec Yasmin Rahini, analyste principale en recherche chez Piper Sandler le 7 ao没t 2025 脿 11h00 EST. L'entreprise se sp茅cialise dans le d茅veloppement de traitements ciblant le d茅s茅quilibre entre excitation et inhibition neuronales dans les troubles du SNC.
Praxis Precision Medicines (NASDAQ:PRAX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien f眉r Erkrankungen des zentralen Nervensystems spezialisiert hat, hat seine Teilnahme an einem bevorstehenden virtuellen Gespr盲ch angek眉ndigt. CEO Marcio Souza wird am 7. August 2025 um 11:00 Uhr EST mit Yasmin Rahini, Senior Research Analyst bei Piper Sandler, diskutieren. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen, die das Ungleichgewicht zwischen neuronaler Erregung und Hemmung bei ZNS-Erkrankungen adressieren.
- None.
- None.
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST.
The event will be webcast live and the registration link can be found .
About Praxis鈥�
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum鈩�, and antisense oligonucleotide (ASO) platform, Solidus鈩�, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit聽and follow us on聽,听,听补苍诲听.
Investor Contact:聽 Praxis Precision Medicines聽 [email protected]聽 857-702-9452聽 聽 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat with Piper Sandler?
Who will represent Praxis Precision Medicines at the Piper Sandler fireside chat?
What type of company is Praxis Precision Medicines (PRAX)?
How can investors access the Praxis Precision Medicines fireside chat?
